Cost-Effectiveness of CT Screening in the National Lung Screening Trial
Top Cited Papers
- 6 November 2014
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 371 (19), 1793-1802
- https://doi.org/10.1056/nejmoa1312547
Abstract
The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) as compared with chest radiography reduced lung-cancer mortality. We examined the cost-effectiveness of screening with low-dose CT in the NLST. We estimated mean life-years, quality-adjusted life-years (QALYs), costs per person, and incremental cost-effectiveness ratios (ICERs) for three alternative strategies: screening with low-dose CT, screening with radiography, and no screening. Estimations of life-years were based on the number of observed deaths that occurred during the trial and the projected survival of persons who were alive at the end of the trial. Quality adjustments were derived from a subgroup of participants who were selected to complete quality-of-life surveys. Costs were based on utilization rates and Medicare reimbursements. We also performed analyses of subgroups defined according to age, sex, smoking history, and risk of lung cancer and performed sensitivity analyses based on several assumptions. As compared with no screening, screening with low-dose CT cost an additional $1,631 per person (95% confidence interval [CI], 1,557 to 1,709) and provided an additional 0.0316 life-years per person (95% CI, 0.0154 to 0.0478) and 0.0201 QALYs per person (95% CI, 0.0088 to 0.0314). The corresponding ICERs were $52,000 per life-year gained (95% CI, 34,000 to 106,000) and $81,000 per QALY gained (95% CI, 52,000 to 186,000). However, the ICERs varied widely in subgroup and sensitivity analyses. We estimated that screening for lung cancer with low-dose CT would cost $81,000 per QALY gained, but we also determined that modest changes in our assumptions would greatly alter this figure. The determination of whether screening outside the trial will be cost-effective will depend on how screening is implemented. (Funded by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.)Keywords
This publication has 34 references indexed in Scilit:
- Results of Initial Low-Dose Computed Tomographic Screening for Lung CancerThe New England Journal of Medicine, 2013
- Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: The model used by the American College of Radiology arm of the National Lung Screening TrialContemporary Clinical Trials, 2013
- Estimating Overdiagnosis in Low-Dose Computed Tomography Screening for Lung CancerAnnals of Internal Medicine, 2012
- Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United StatesJournal of Thoracic Oncology, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- The National Lung Screening Trial: Overview and Study DesignRadiology, 2011
- The impact of a lung cancer computed tomography screening result on smoking abstinenceEuropean Respiratory Journal, 2010
- Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON)British Journal of Cancer, 2009
- Survival of Patients with Stage I Lung Cancer Detected on CT ScreeningThe New England Journal of Medicine, 2006
- Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian settingLung Cancer, 2005